ID   BMAL1_HUMAN             Reviewed;         626 AA.
AC   O00327; A2I2N6; A8K645; B5ME11; B7WPG7; D3DQW6; O00313; O00314; O00315;
AC   O00316; O00317; Q4G136; Q8IUT4; Q99631; Q99649;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-AUG-2003, sequence version 2.
DT   07-APR-2021, entry version 212.
DE   RecName: Full=Aryl hydrocarbon receptor nuclear translocator-like protein 1;
DE   AltName: Full=Basic-helix-loop-helix-PAS protein MOP3;
DE   AltName: Full=Brain and muscle ARNT-like 1;
DE   AltName: Full=Class E basic helix-loop-helix protein 5;
DE            Short=bHLHe5;
DE   AltName: Full=Member of PAS protein 3;
DE   AltName: Full=PAS domain-containing protein 3;
DE   AltName: Full=bHLH-PAS protein JAP3;
GN   Name=ARNTL; Synonyms=BHLHE5, BMAL1, MOP3, PASD3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND ALTERNATIVE SPLICING
RP   (ISOFORMS BMAL1A; BMAL1B; BMAL1C; BMAL1D; BMAL1E AND BMAL1F).
RC   TISSUE=Brain;
RX   PubMed=9144434; DOI=10.1006/bbrc.1997.6371;
RA   Ikeda M., Nomura M.;
RT   "cDNA cloning and tissue-specific expression of a novel basic helix-loop-
RT   helix/PAS protein (BMAL1) and identification of alternatively spliced
RT   variants with alternative translation initiation site usage.";
RL   Biochem. Biophys. Res. Commun. 233:258-264(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MOP3), AND INTERACTION WITH HSP90 AND
RP   AHR.
RC   TISSUE=Fetal brain;
RX   PubMed=9079689; DOI=10.1074/jbc.272.13.8581;
RA   Hogenesch J.B., Chan W.K., Jackiw V.H., Brown R.C., Gu Y.-Z.,
RA   Pray-Grant M., Perdew G.H., Bradfield C.A.;
RT   "Characterization of a subset of the basic-helix-loop-helix-PAS superfamily
RT   that interacts with components of the dioxin signaling pathway.";
RL   J. Biol. Chem. 272:8581-8593(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BMAL1B).
RA   Tian H., Russell D.W., McKnight S.L.;
RT   "JAP3: a novel ARNT-like bHLH-PAS protein.";
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BMAL1B).
RX   PubMed=9576906; DOI=10.1073/pnas.95.10.5474;
RA   Hogenesch J.B., Gu Y.Z., Jain S., Bradfield C.A.;
RT   "The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active
RT   complexes with circadian and hypoxia factors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:5474-5479(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS BMAL1B AND 9).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kripke D.F., Klimecki W.;
RT   "ARNTL resequence.";
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 8 AND BMAL1A).
RC   TISSUE=Brain, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH CLOCK.
RX   PubMed=9616112; DOI=10.1126/science.280.5369.1564;
RA   Gekakis N., Staknis D., Nguyen H.B., Davis F.C., Wilsbacher L.D.,
RA   King D.P., Takahashi J.S., Weitz C.J.;
RT   "Role of the CLOCK protein in the mammalian circadian mechanism.";
RL   Science 280:1564-1569(1998).
RN   [11]
RP   FUNCTION, DNA-BINDING, AND ACTIVITY REGULATION.
RX   PubMed=11441146; DOI=10.1126/science.1060698;
RA   Rutter J., Reick M., Wu L.C., McKnight S.L.;
RT   "Regulation of clock and NPAS2 DNA binding by the redox state of NAD
RT   cofactors.";
RL   Science 293:510-514(2001).
RN   [12]
RP   FUNCTION.
RX   PubMed=12738229; DOI=10.1016/s0022-2828(03)00051-8;
RA   Schoenhard J.A., Smith L.H., Painter C.A., Eren M., Johnson C.H.,
RA   Vaughan D.E.;
RT   "Regulation of the PAI-1 promoter by circadian clock components:
RT   differential activation by BMAL1 and BMAL2.";
RL   J. Mol. Cell. Cardiol. 35:473-481(2003).
RN   [13]
RP   INTERACTION WITH KAT2B AND EP300.
RX   PubMed=14645221; DOI=10.1074/jbc.m311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the vascular
RT   clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [14]
RP   MUTAGENESIS OF SER-9; SER-10; ALA-611 AND GLY-612.
RX   PubMed=16474406; DOI=10.1038/ng1745;
RA   Sato T.K., Yamada R.G., Ukai H., Baggs J.E., Miraglia L.J., Kobayashi T.J.,
RA   Welsh D.K., Kay S.A., Ueda H.R., Hogenesch J.B.;
RT   "Feedback repression is required for mammalian circadian clock function.";
RL   Nat. Genet. 38:312-319(2006).
RN   [15]
RP   FUNCTION.
RX   PubMed=18587630; DOI=10.1007/s11010-008-9846-x;
RA   Li R., Yue J., Zhang Y., Zhou L., Hao W., Yuan J., Qiang B., Ding J.M.,
RA   Peng X., Cao J.M.;
RT   "CLOCK/BMAL1 regulates human nocturnin transcription through binding to the
RT   E-box of nocturnin promoter.";
RL   Mol. Cell. Biochem. 317:169-177(2008).
RN   [16]
RP   INTERACTION WITH KDM5A.
RX   PubMed=21960634; DOI=10.1126/science.1206022;
RA   DiTacchio L., Le H.D., Vollmers C., Hatori M., Witcher M., Secombe J.,
RA   Panda S.;
RT   "Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences
RT   the circadian clock.";
RL   Science 333:1881-1885(2011).
RN   [17]
RP   REVIEW.
RX   PubMed=23576606; DOI=10.1152/ajpregu.00066.2013;
RA   Richards J., Gumz M.L.;
RT   "Mechanism of the circadian clock in physiology.";
RL   Am. J. Physiol. 304:R1053-R1064(2013).
RN   [18]
RP   FUNCTION.
RX   PubMed=23955654; DOI=10.1007/s00403-013-1403-0;
RA   Watabe Y., Tomioka M., Watabe A., Aihara M., Shimba S., Inoue H.;
RT   "The clock gene brain and muscle Arnt-like protein-1 (BMAL1) is involved in
RT   hair growth.";
RL   Arch. Dermatol. Res. 305:755-761(2013).
RN   [19]
RP   FUNCTION.
RX   PubMed=23785138; DOI=10.1523/jneurosci.2757-12.2013;
RA   Baeza-Raja B., Eckel-Mahan K., Zhang L., Vagena E., Tsigelny I.F.,
RA   Sassone-Corsi P., Ptacek L.J., Akassoglou K.;
RT   "p75 neurotrophin receptor is a clock gene that regulates oscillatory
RT   components of circadian and metabolic networks.";
RL   J. Neurosci. 33:10221-10234(2013).
RN   [20]
RP   REVIEW.
RX   PubMed=23303907; DOI=10.1152/physrev.00016.2012;
RA   Eckel-Mahan K., Sassone-Corsi P.;
RT   "Metabolism and the circadian clock converge.";
RL   Physiol. Rev. 93:107-135(2013).
RN   [21]
RP   INTERACTION WITH CIART.
RX   PubMed=24385426; DOI=10.1074/jbc.m113.534651;
RA   Annayev Y., Adar S., Chiou Y.Y., Lieb J., Sancar A., Ye R.;
RT   "Gene model 129 (Gm129) encodes a novel transcriptional repressor that
RT   modulates circadian gene expression.";
RL   J. Biol. Chem. 289:5013-5024(2014).
RN   [22]
RP   FUNCTION IN HAIR GROWTH, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=24005054; DOI=10.1038/jid.2013.366;
RA   Al-Nuaimi Y., Hardman J.A., Biro T., Haslam I.S., Philpott M.P., Toth B.I.,
RA   Farjo N., Farjo B., Baier G., Watson R.E., Grimaldi B., Kloepper J.E.,
RA   Paus R.;
RT   "A meeting of two chronobiological systems: circadian proteins Period1 and
RT   BMAL1 modulate the human hair cycle clock.";
RL   J. Invest. Dermatol. 134:610-619(2014).
RN   [23]
RP   INTERACTION WITH UBE3A, UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=24728990; DOI=10.1093/nar/gku225;
RA   Gossan N.C., Zhang F., Guo B., Jin D., Yoshitane H., Yao A., Glossop N.,
RA   Zhang Y.Q., Fukada Y., Meng Q.J.;
RT   "The E3 ubiquitin ligase UBE3A is an integral component of the molecular
RT   circadian clock through regulating the BMAL1 transcription factor.";
RL   Nucleic Acids Res. 42:5765-5775(2014).
RN   [24]
RP   REVIEW.
RX   PubMed=23916625; DOI=10.1016/j.tcb.2013.07.002;
RA   Partch C.L., Green C.B., Takahashi J.S.;
RT   "Molecular architecture of the mammalian circadian clock.";
RL   Trends Cell Biol. 24:90-99(2014).
RN   [25]
RP   INTERACTION WITH PASD1.
RX   PubMed=25936801; DOI=10.1016/j.molcel.2015.03.031;
RA   Michael A.K., Harvey S.L., Sammons P.J., Anderson A.P., Kopalle H.M.,
RA   Banham A.H., Partch C.L.;
RT   "Cancer/testis antigen PASD1 silences the circadian clock.";
RL   Mol. Cell 58:743-754(2015).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH CLOCK.
RX   PubMed=28985504; DOI=10.1016/j.molcel.2017.09.008;
RA   Lin R., Mo Y., Zha H., Qu Z., Xie P., Zhu Z.J., Xu Y., Xiong Y., Guan K.L.;
RT   "CLOCK acetylates ASS1 to drive circadian rhythm of ureagenesis.";
RL   Mol. Cell 68:198-209(2017).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-259, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   INTERACTION WITH PIWIL2.
RX   PubMed=28903391; DOI=10.18632/oncotarget.18973;
RA   Lu Y., Zheng X., Hu W., Bian S., Zhang Z., Tao D., Liu Y., Ma Y.;
RT   "Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating
RT   the stability and activity of BMAL1 and CLOCK.";
RL   Oncotarget 8:54913-54924(2017).
RN   [29]
RP   DEUBIQUITINATION BY USP9X, AND INTERACTION WITH USP9X.
RX   PubMed=29626158; DOI=10.1042/bcj20180005;
RA   Zhang Y., Duan C., Yang J., Chen S., Liu Q., Zhou L., Huang Z., Xu Y.,
RA   Xu G.;
RT   "Deubiquitinating enzyme USP9X regulates cellular clock function by
RT   modulating the ubiquitination and degradation of a core circadian protein
RT   BMAL1.";
RL   Biochem. J. 475:1507-1522(2018).
RN   [30]
RP   INTERACTION WITH HNF4A.
RX   PubMed=30530698; DOI=10.1073/pnas.1816411115;
RA   Qu M., Duffy T., Hirota T., Kay S.A.;
RT   "Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-
RT   specific circadian networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E12305-E12312(2018).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 66-128 IN COMPLEX WITH CLOCK AND
RP   DNA, FUNCTION, ACTIVITY REGULATION, SUBUNIT, PHOSPHORYLATION AT SER-78, AND
RP   MUTAGENESIS OF SER-78; MET-88; SER-90 AND LEU-125.
RX   PubMed=23229515; DOI=10.1038/cr.2012.170;
RA   Wang Z., Wu Y., Li L., Su X.D.;
RT   "Intermolecular recognition revealed by the complex structure of human
RT   CLOCK-BMAL1 basic helix-loop-helix domains with E-box DNA.";
RL   Cell Res. 23:213-224(2013).
CC   -!- FUNCTION: Transcriptional activator which forms a core component of the
CC       circadian clock. The circadian clock, an internal time-keeping system,
CC       regulates various physiological processes through the generation of
CC       approximately 24 hour circadian rhythms in gene expression, which are
CC       translated into rhythms in metabolism and behavior. It is derived from
CC       the Latin roots 'circa' (about) and 'diem' (day) and acts as an
CC       important regulator of a wide array of physiological functions
CC       including metabolism, sleep, body temperature, blood pressure,
CC       endocrine, immune, cardiovascular, and renal function. Consists of two
CC       major components: the central clock, residing in the suprachiasmatic
CC       nucleus (SCN) of the brain, and the peripheral clocks that are present
CC       in nearly every tissue and organ system. Both the central and
CC       peripheral clocks can be reset by environmental cues, also known as
CC       Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the
CC       central clock is light, which is sensed by retina and signals directly
CC       to the SCN. The central clock entrains the peripheral clocks through
CC       neuronal and hormonal signals, body temperature and feeding-related
CC       cues, aligning all clocks with the external light/dark cycle. Circadian
CC       rhythms allow an organism to achieve temporal homeostasis with its
CC       environment at the molecular level by regulating gene expression to
CC       create a peak of protein expression once every 24 hours to control when
CC       a particular physiological process is most active with respect to the
CC       solar day. Transcription and translation of core clock components
CC       (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2, PER1, PER2, PER3, CRY1 and
CC       CRY2) plays a critical role in rhythm generation, whereas delays
CC       imposed by post-translational modifications (PTMs) are important for
CC       determining the period (tau) of the rhythms (tau refers to the period
CC       of a rhythm and is the length, in time, of one complete cycle). A
CC       diurnal rhythm is synchronized with the day/night cycle, while the
CC       ultradian and infradian rhythms have a period shorter and longer than
CC       24 hours, respectively. Disruptions in the circadian rhythms contribute
CC       to the pathology of cardiovascular diseases, cancer, metabolic
CC       syndromes and aging. A transcription/translation feedback loop (TTFL)
CC       forms the core of the molecular circadian clock mechanism.
CC       Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or ARNTL2/BMAL2,
CC       form the positive limb of the feedback loop, act in the form of a
CC       heterodimer and activate the transcription of core clock genes and
CC       clock-controlled genes (involved in key metabolic processes), harboring
CC       E-box elements (5'-CACGTG-3') within their promoters. The core clock
CC       genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form
CC       the negative limb of the feedback loop and interact with the
CC       CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer inhibiting its
CC       activity and thereby negatively regulating their own expression. This
CC       heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G,
CC       which form a second feedback loop and which activate and repress
CC       ARNTL/BMAL1 transcription, respectively. ARNTL/BMAL1 positively
CC       regulates myogenesis and negatively regulates adipogenesis via the
CC       transcriptional control of the genes of the canonical Wnt signaling
CC       pathway. Plays a role in normal pancreatic beta-cell function;
CC       regulates glucose-stimulated insulin secretion via the regulation of
CC       antioxidant genes NFE2L2/NRF2 and its targets SESN2, PRDX3, CCLC and
CC       CCLM. Negatively regulates the mTORC1 signaling pathway; regulates the
CC       expression of MTOR and DEPTOR. Controls diurnal oscillations of Ly6C
CC       inflammatory monocytes; rhythmic recruitment of the PRC2 complex
CC       imparts diurnal variation to chemokine expression that is necessary to
CC       sustain Ly6C monocyte rhythms. Regulates the expression of HSD3B2,
CC       STAR, PTGS2, CYP11A1, CYP19A1 and LHCGR in the ovary and also the genes
CC       involved in hair growth. Plays an important role in adult hippocampal
CC       neurogenesis by regulating the timely entry of neural stem/progenitor
CC       cells (NSPCs) into the cell cycle and the number of cell divisions that
CC       take place prior to cell-cycle exit. Regulates the circadian expression
CC       of CIART and KLF11. The CLOCK-ARNTL/BMAL1 heterodimer regulates the
CC       circadian expression of SERPINE1/PAI1, VWF, B3, CCRN4L/NOC, NAMPT, DBP,
CC       MYOD1, PPARGC1A, PPARGC1B, SIRT1, GYS2, F7, NGFR, GNRHR, BHLHE40/DEC1,
CC       ATF4, MTA1, KLF10 and also genes implicated in glucose and lipid
CC       metabolism. Promotes rhythmic chromatin opening, regulating the DNA
CC       accessibility of other transcription factors. The NPAS2-ARNTL/BMAL1
CC       heterodimer positively regulates the expression of MAOA, F7 and LDHA
CC       and modulates the circadian rhythm of daytime contrast sensitivity by
CC       regulating the rhythmic expression of adenylate cyclase type 1 (ADCY1)
CC       in the retina. The preferred binding motif for the CLOCK-ARNTL/BMAL1
CC       heterodimer is 5'-CACGTGA-3', which contains a flanking Ala residue in
CC       addition to the canonical 6-nucleotide E-box sequence
CC       (PubMed:23229515). CLOCK specifically binds to the half-site 5'-CAC-3',
CC       while ARNTL binds to the half-site 5'-GTGA-3' (PubMed:23229515). The
CC       CLOCK-ARNTL/BMAL1 heterodimer also recognizes the non-canonical E-box
CC       motifs 5'-AACGTGA-3' and 5'-CATGTGA-3' (PubMed:23229515). Essential for
CC       the rhythmic interaction of CLOCK with ASS1 and plays a critical role
CC       in positively regulating CLOCK-mediated acetylation of ASS1
CC       (PubMed:28985504). Plays a role in protecting against lethal sepsis by
CC       limiting the expression of immune checkpoint protein CD274 in
CC       macrophages in a PKM2-dependent manner (By similarity). Regulates the
CC       diurnal rhythms of skeletal muscle metabolism via transcriptional
CC       activation of genes promoting triglyceride synthesis (DGAT2) and
CC       metabolic efficiency (COQ10B) (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WTL8, ECO:0000269|PubMed:11441146,
CC       ECO:0000269|PubMed:12738229, ECO:0000269|PubMed:18587630,
CC       ECO:0000269|PubMed:23785138, ECO:0000269|PubMed:23955654,
CC       ECO:0000269|PubMed:24005054, ECO:0000269|PubMed:28985504}.
CC   -!- ACTIVITY REGULATION: There is conflicting data about the effect of NAD
CC       cofactors on activity. PubMed:11441146 suggests that the redox state of
CC       the cell can modulate the transcriptional activity of the CLOCK-
CC       ARNTL/BMAL1 heterodimer; NADH and NADPH enhance the DNA-binding
CC       activity of the heterodimer. PubMed:23229515 reports that NADH and
CC       NADPH have no significant effect on DNA-binding activity of the CLOCK-
CC       ARNTL/BMAL1 heterodimer. {ECO:0000269|PubMed:11441146,
CC       ECO:0000269|PubMed:23229515}.
CC   -!- SUBUNIT: Component of the circadian clock oscillator which includes the
CC       CRY1/2 proteins, CLOCK or NPAS2, ARNTL/BMAL1 or ARNTL2/BMAL2, CSNK1D
CC       and/or CSNK1E, TIMELESS and the PER1/2/3 proteins (By similarity).
CC       Forms a heterodimer with CLOCK (PubMed:9616112, PubMed:23229515). The
CC       CLOCK-ARNTL/BMAL1 heterodimer is required for E-box-dependent
CC       transactivation, for CLOCK nuclear translocation and degradation, and,
CC       for phosphorylation of both CLOCK and ARNTL/BMAL1 (By similarity). Part
CC       of a nuclear complex which also includes RACK1 and PRKCA; RACK1 and
CC       PRKCA are recruited to the complex in a circadian manner (By
CC       similarity). Interacts with NPAS2 (By similarity). Interacts with EZH2
CC       (By similarity). Interacts with SUMO3 (By similarity). Interacts with
CC       SIRT1 (By similarity). Interacts with AHR (PubMed:9079689). Interacts
CC       with ID1, ID2 and ID3 (By similarity). Interacts with DDX4 (By
CC       similarity). Interacts with OGT (By similarity). Interacts with EED and
CC       SUZ12 (By similarity). Interacts with MTA1 (By similarity). Interacts
CC       with CIART (PubMed:24385426). Interacts with HSP90 (PubMed:9079689).
CC       Interacts with KAT2B and EP300 (PubMed:14645221). Interacts with
CC       BHLHE40/DEC1 and BHLHE41/DEC2 (By similarity). Interacts with RELB and
CC       the interaction is enhanced in the presence of CLOCK (By similarity).
CC       Interacts with PER1, PER2, CRY1 and CRY2 and this interaction requires
CC       a translocation to the nucleus (By similarity). Interaction of the
CC       CLOCK-ARNTL/BMAL1 heterodimer with PER or CRY inhibits transcription
CC       activation (By similarity). Interaction of the CLOCK-ARNTL/BMAL1 with
CC       CRY1 is independent of DNA but with PER2 is off DNA (By similarity).
CC       The CLOCK-ARNTL/BMAL1 heterodimer interacts with GSK3B (By similarity).
CC       Interacts with KDM5A (PubMed:21960634). Interacts with KMT2A; in a
CC       circadian manner (By similarity). Interacts with UBE3A
CC       (PubMed:24728990). Interacts with PRKCG (By similarity). Interacts with
CC       MAGEL2 (By similarity). Interacts with NCOA2 (By similarity). Interacts
CC       with THRAP3 (By similarity). The CLOCK-ARNTL/BMAL1 heterodimer
CC       interacts with PASD1 (PubMed:25936801). Interacts with PASD1
CC       (PubMed:25936801). Interacts with USP9X (PubMed:29626158). Interacts
CC       with PIWIL2 (via PIWI domain) (PubMed:28903391). Interacts with HDAC3
CC       (By similarity). Interacts with HNF4A (PubMed:30530698).
CC       {ECO:0000250|UniProtKB:Q9WTL8, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:21960634, ECO:0000269|PubMed:23229515,
CC       ECO:0000269|PubMed:24385426, ECO:0000269|PubMed:24728990,
CC       ECO:0000269|PubMed:25936801, ECO:0000269|PubMed:28903391,
CC       ECO:0000269|PubMed:28985504, ECO:0000269|PubMed:29626158,
CC       ECO:0000269|PubMed:30530698, ECO:0000269|PubMed:9079689,
CC       ECO:0000269|PubMed:9616112}.
CC   -!- INTERACTION:
CC       O00327; O15516: CLOCK; NbExp=4; IntAct=EBI-1794206, EBI-1794265;
CC       O00327; D0VY79: HIF1A; NbExp=3; IntAct=EBI-1794206, EBI-10179332;
CC       O00327-8; O14977: AZIN1; NbExp=3; IntAct=EBI-11991546, EBI-1054824;
CC       O00327-8; O15516: CLOCK; NbExp=6; IntAct=EBI-11991546, EBI-1794265;
CC       O00327-8; Q96HY7: DHTKD1; NbExp=3; IntAct=EBI-11991546, EBI-11022401;
CC       O00327-8; Q99814: EPAS1; NbExp=3; IntAct=EBI-11991546, EBI-447470;
CC       O00327-8; Q99743: NPAS2; NbExp=10; IntAct=EBI-11991546, EBI-3932727;
CC       O00327-8; Q8WVT3: TRAPPC12; NbExp=3; IntAct=EBI-11991546, EBI-2819919;
CC       O00327-8; Q9H0C1: ZMYND12; NbExp=5; IntAct=EBI-11991546, EBI-12030590;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00981,
CC       ECO:0000269|PubMed:24005054}. Cytoplasm {ECO:0000250|UniProtKB:Q9WTL8}.
CC       Nucleus, PML body {ECO:0000250|UniProtKB:Q9WTL8}. Note=Shuttles between
CC       the nucleus and the cytoplasm and this nucleocytoplasmic shuttling is
CC       essential for the nuclear accumulation of CLOCK, target gene
CC       transcription and the degradation of the CLOCK-ARNTL/BMAL1 heterodimer.
CC       The sumoylated form localizes in the PML body. Sequestered to the
CC       cytoplasm in the presence of ID2. {ECO:0000250|UniProtKB:Q9WTL8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=BMAL1B; Synonyms=JAP3;
CC         IsoId=O00327-2; Sequence=Displayed;
CC       Name=BMAL1A;
CC         IsoId=O00327-1; Sequence=VSP_002094;
CC       Name=BMAL1C;
CC         IsoId=O00327-3; Sequence=VSP_002096, VSP_002097;
CC       Name=BMAL1D;
CC         IsoId=O00327-4; Sequence=VSP_002098;
CC       Name=BMAL1E;
CC         IsoId=O00327-5; Sequence=VSP_002099, VSP_002100;
CC       Name=BMAL1F;
CC         IsoId=O00327-6; Sequence=VSP_002101, VSP_002102;
CC       Name=MOP3;
CC         IsoId=O00327-7; Sequence=VSP_002095;
CC       Name=8;
CC         IsoId=O00327-8; Sequence=VSP_035457;
CC       Name=9;
CC         IsoId=O00327-9; Sequence=VSP_002094, VSP_035457;
CC   -!- TISSUE SPECIFICITY: Hair follicles (at protein level). Highly expressed
CC       in the adult brain, skeletal muscle and heart.
CC       {ECO:0000269|PubMed:24005054}.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation
CC       (PubMed:24728990). Deubiquitinated by USP9X (PubMed:29626158).
CC       {ECO:0000269|PubMed:24728990, ECO:0000269|PubMed:29626158}.
CC   -!- PTM: O-glycosylated; contains O-GlcNAc. O-glycosylation by OGT prevents
CC       protein degradation by inhibiting ubiquitination. It also stabilizes
CC       the CLOCK-ARNTL/BMAL1 heterodimer thereby increasing CLOCK-ARNTL/BMAL1-
CC       mediated transcription of genes in the negative loop of the circadian
CC       clock such as PER1/2/3 and CRY1/2. {ECO:0000250|UniProtKB:Q9WTL8}.
CC   -!- PTM: Acetylated on Lys-538 upon dimerization with CLOCK. Acetylation
CC       facilitates CRY1-mediated repression. Deacetylated by SIRT1, which may
CC       result in decreased protein stability. {ECO:0000250|UniProtKB:Q9WTL8}.
CC   -!- PTM: Phosphorylated upon dimerization with CLOCK. Phosphorylation
CC       enhances the transcriptional activity, alters the subcellular
CC       localization and decreases the stability of the CLOCK-ARNTL/BMAL1
CC       heterodimer by promoting its degradation. Phosphorylation shows
CC       circadian variations in the liver with a peak between CT10 to CT14.
CC       Phosphorylation at Ser-90 by CK2 is essential for its nuclear
CC       localization, its interaction with CLOCK and controls CLOCK nuclear
CC       entry (By similarity). Dephosphorylation at Ser-78 is important for
CC       dimerization with CLOCK and transcriptional activity (PubMed:23229515).
CC       {ECO:0000250|UniProtKB:Q9WTL8, ECO:0000269|PubMed:23229515}.
CC   -!- PTM: Sumoylated on Lys-259 upon dimerization with CLOCK. Predominantly
CC       conjugated to poly-SUMO2/3 rather than SUMO1 and the level of these
CC       conjugates undergo rhythmic variation, peaking at CT9-CT12. Sumoylation
CC       localizes it exclusively to the PML body and promotes its
CC       ubiquitination in the PML body, ubiquitin-dependent proteasomal
CC       degradation and the transcriptional activity of the CLOCK-ARNTL/BMAL1
CC       heterodimer. {ECO:0000250|UniProtKB:Q9WTL8}.
CC   -!- PTM: Undergoes lysosome-mediated degradation in a time-dependent manner
CC       in the liver. {ECO:0000250|UniProtKB:Q9WTL8}.
CC   -!- MISCELLANEOUS: CLOCK-ARNTL/BMAL1 double mutations within the PAS
CC       domains result in synergistic desensitization to high levels of CRY on
CC       repression of CLOCK-ARNTL/BMAL1 transcriptional activity of PER1 and,
CC       disrupt circadian rhythmicity.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D89722; BAA19968.1; -; mRNA.
DR   EMBL; AB000812; BAA19935.1; -; mRNA.
DR   EMBL; AB000813; BAA19936.1; -; Genomic_DNA.
DR   EMBL; AB000814; BAA19937.1; -; mRNA.
DR   EMBL; AB000815; BAA19938.1; -; mRNA.
DR   EMBL; AB000816; BAA19939.1; -; mRNA.
DR   EMBL; U51627; AAC51213.1; -; mRNA.
DR   EMBL; U60415; AAB37248.1; -; mRNA.
DR   EMBL; AF044288; AAC24353.1; -; mRNA.
DR   EMBL; AK095749; BAG53120.1; -; mRNA.
DR   EMBL; AK291510; BAF84199.1; -; mRNA.
DR   EMBL; EF015894; ABM64205.1; -; Genomic_DNA.
DR   EMBL; AC016884; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022878; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68504.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68505.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68510.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68511.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68513.1; -; Genomic_DNA.
DR   EMBL; BC016674; AAH16674.1; -; mRNA.
DR   EMBL; BC031214; AAH31214.1; -; mRNA.
DR   EMBL; BC041129; AAH41129.2; -; mRNA.
DR   CCDS; CCDS31430.1; -. [O00327-8]
DR   CCDS; CCDS44543.1; -. [O00327-9]
DR   CCDS; CCDS73259.1; -. [O00327-2]
DR   CCDS; CCDS76387.1; -. [O00327-1]
DR   PIR; JC5405; JC5405.
DR   PIR; JC5407; JC5407.
DR   PIR; PC4288; PC4288.
DR   PIR; PC4289; PC4289.
DR   RefSeq; NP_001025443.1; NM_001030272.2. [O00327-8]
DR   RefSeq; NP_001025444.1; NM_001030273.2. [O00327-9]
DR   RefSeq; NP_001169.3; NM_001178.5. [O00327-8]
DR   RefSeq; NP_001284648.1; NM_001297719.1. [O00327-2]
DR   RefSeq; NP_001284651.1; NM_001297722.1. [O00327-2]
DR   RefSeq; NP_001284653.1; NM_001297724.1. [O00327-1]
DR   RefSeq; XP_011518414.1; XM_011520112.2.
DR   RefSeq; XP_011518415.1; XM_011520113.1.
DR   RefSeq; XP_016873231.1; XM_017017742.1.
DR   RefSeq; XP_016873232.1; XM_017017743.1.
DR   RefSeq; XP_016873235.1; XM_017017746.1.
DR   RefSeq; XP_016873236.1; XM_017017747.1.
DR   RefSeq; XP_016873237.1; XM_017017748.1. [O00327-9]
DR   PDB; 4H10; X-ray; 2.40 A; A=66-128.
DR   PDBsum; 4H10; -.
DR   SMR; O00327; -.
DR   BioGRID; 106899; 96.
DR   ComplexPortal; CPX-3229; CLOCK-BMAL1 transcription complex.
DR   CORUM; O00327; -.
DR   DIP; DIP-46008N; -.
DR   IntAct; O00327; 23.
DR   MINT; O00327; -.
DR   STRING; 9606.ENSP00000384517; -.
DR   iPTMnet; O00327; -.
DR   PhosphoSitePlus; O00327; -.
DR   BioMuta; ARNTL; -.
DR   jPOST; O00327; -.
DR   MassIVE; O00327; -.
DR   PaxDb; O00327; -.
DR   PeptideAtlas; O00327; -.
DR   PRIDE; O00327; -.
DR   ProteomicsDB; 47841; -. [O00327-2]
DR   ProteomicsDB; 47842; -. [O00327-1]
DR   ProteomicsDB; 47843; -. [O00327-3]
DR   ProteomicsDB; 47844; -. [O00327-4]
DR   ProteomicsDB; 47845; -. [O00327-5]
DR   ProteomicsDB; 47846; -. [O00327-6]
DR   ProteomicsDB; 47847; -. [O00327-7]
DR   ProteomicsDB; 47848; -. [O00327-8]
DR   ProteomicsDB; 47849; -. [O00327-9]
DR   Antibodypedia; 11861; 529 antibodies.
DR   DNASU; 406; -.
DR   Ensembl; ENST00000389707; ENSP00000374357; ENSG00000133794. [O00327-8]
DR   Ensembl; ENST00000401424; ENSP00000385915; ENSG00000133794. [O00327-9]
DR   Ensembl; ENST00000403290; ENSP00000384517; ENSG00000133794. [O00327-2]
DR   Ensembl; ENST00000403482; ENSP00000385897; ENSG00000133794. [O00327-7]
DR   Ensembl; ENST00000403510; ENSP00000385581; ENSG00000133794. [O00327-2]
DR   Ensembl; ENST00000529388; ENSP00000433571; ENSG00000133794. [O00327-2]
DR   GeneID; 406; -.
DR   KEGG; hsa:406; -.
DR   UCSC; uc001mko.4; human. [O00327-2]
DR   CTD; 406; -.
DR   DisGeNET; 406; -.
DR   GeneCards; ARNTL; -.
DR   HGNC; HGNC:701; ARNTL.
DR   HPA; ENSG00000133794; Low tissue specificity.
DR   MIM; 602550; gene.
DR   neXtProt; NX_O00327; -.
DR   OpenTargets; ENSG00000133794; -.
DR   PharmGKB; PA24996; -.
DR   VEuPathDB; HostDB:ENSG00000133794.17; -.
DR   eggNOG; KOG3561; Eukaryota.
DR   GeneTree; ENSGT00940000157523; -.
DR   HOGENOM; CLU_011864_2_2_1; -.
DR   InParanoid; O00327; -.
DR   OMA; YHHEDIP; -.
DR   OrthoDB; 331262at2759; -.
DR   PhylomeDB; O00327; -.
DR   TreeFam; TF319983; -.
DR   PathwayCommons; O00327; -.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SIGNOR; O00327; -.
DR   BioGRID-ORCS; 406; 8 hits in 1009 CRISPR screens.
DR   ChiTaRS; ARNTL; human.
DR   GeneWiki; ARNTL; -.
DR   GenomeRNAi; 406; -.
DR   Pharos; O00327; Tbio.
DR   PRO; PR:O00327; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; O00327; protein.
DR   Bgee; ENSG00000133794; Expressed in left lobe of thyroid gland and 228 other tissues.
DR   ExpressionAtlas; O00327; baseline and differential.
DR   Genevisible; O00327; HS.
DR   GO; GO:0034751; C:aryl hydrocarbon receptor complex; IBA:GO_Central.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0033391; C:chromatoid body; ISS:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0005667; C:transcription regulator complex; IPI:MGI.
DR   GO; GO:0017162; F:aryl hydrocarbon receptor binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:BHF-UCL.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:GO_Central.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; IDA:BHF-UCL.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IBA:GO_Central.
DR   GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000323; P:negative regulation of glucocorticoid receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; ISS:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0042753; P:positive regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:1901985; P:positive regulation of protein acetylation; IMP:UniProtKB.
DR   GO; GO:2001016; P:positive regulation of skeletal muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:2000772; P:regulation of cellular senescence; ISS:UniProtKB.
DR   GO; GO:0042634; P:regulation of hair cycle; IMP:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0050767; P:regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:2000074; P:regulation of type B pancreatic cell development; ISS:UniProtKB.
DR   GO; GO:0051775; P:response to redox state; IDA:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   IDEAL; IID00426; -.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Biological rhythms; Cytoplasm; DNA-binding; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..626
FT                   /note="Aryl hydrocarbon receptor nuclear translocator-like
FT                   protein 1"
FT                   /id="PRO_0000127156"
FT   DOMAIN          72..125
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          143..215
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          326..396
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          401..444
FT                   /note="PAC"
FT   REGION          508..588
FT                   /note="Interaction with CIART"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   MOTIF           36..41
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   MOTIF           142..152
FT                   /note="Nuclear export signal 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   MOTIF           361..369
FT                   /note="Nuclear export signal 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   SITE            77
FT                   /note="Interaction with E-box DNA"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   SITE            80
FT                   /note="Interaction with E-box DNA"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   SITE            81
FT                   /note="Interaction with E-box DNA"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   SITE            85
FT                   /note="Interaction with E-box DNA"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   SITE            125
FT                   /note="Important for interaction with CLOCK"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MOD_RES         17
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   MOD_RES         21
FT                   /note="Phosphothreonine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   MOD_RES         78
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:23229515"
FT   MOD_RES         90
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   MOD_RES         538
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   CROSSLNK        252
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2 and SUMO3)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTL8"
FT   CROSSLNK        259
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..59
FT                   /note="MADQRMDISSTISDFMSPGPTDLLSSSLGTSGVDCNRKRKGSSTDYQESMDT
FT                   DKDDPHG -> MSKEAVSLWALTVSLQPPVPLCVCREMTGSGRRKQQCVTLPFISRELC
FT                   FYLLLFPPP (in isoform MOP3)"
FT                   /evidence="ECO:0000303|PubMed:9079689"
FT                   /id="VSP_002095"
FT   VAR_SEQ         1..47
FT                   /note="MADQRMDISSTISDFMSPGPTDLLSSSLGTSGVDCNRKRKGSSTDYQ -> M
FT                   INI (in isoform BMAL1A and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_002094"
FT   VAR_SEQ         224
FT                   /note="T -> R (in isoform BMAL1C)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002096"
FT   VAR_SEQ         225..626
FT                   /note="Missing (in isoform BMAL1C)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002097"
FT   VAR_SEQ         274..391
FT                   /note="Missing (in isoform BMAL1D)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002098"
FT   VAR_SEQ         274
FT                   /note="Missing (in isoform 8 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035457"
FT   VAR_SEQ         278..301
FT                   /note="SFCTIHSTGYLKSWPPTKMGLDED -> AFCTIHSTGYFGIFTTRTSRHIVL
FT                   (in isoform BMAL1E)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002099"
FT   VAR_SEQ         302..626
FT                   /note="Missing (in isoform BMAL1E)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002100"
FT   VAR_SEQ         443..526
FT                   /note="ANVLEGGDPTFPQLTASPHSMDSMLPSGEGGPKRTHPTVPGIPGGTRAGAGK
FT                   IGRMIAEEIMEIHRIRGSSPSSCGSSPLNITS -> SRVDTGHLGQVERCTVLSRPNSR
FT                   FLIAGMFTEPTSWKAGTQPSHSSQHPPTAWTACCPLEKVAQRGPTPLFQGFQGEPGLGQ
FT                   EK (in isoform BMAL1F)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002101"
FT   VAR_SEQ         527..626
FT                   /note="Missing (in isoform BMAL1F)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002102"
FT   MUTAGEN         9
FT                   /note="S->A,E: Enhanced PER1 reporter activity by CLOCK-
FT                   ARNTL/BMAL1."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         9
FT                   /note="S->F: 2-2.5-fold increase in CLOCK-BMAL1
FT                   transcriptional activity in the absence of CRY1. No change
FT                   in repression activity in the presence of CRY1."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         10
FT                   /note="S->A,E: Enhanced PER1 reporter activity by CLOCK-
FT                   ARNTL/BMAL1."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         10
FT                   /note="S->L: 2-2.5-fold increase in CLOCK-ARNTL/BMAL1
FT                   transcriptional activity in the absence of CRY1. No change
FT                   in repression activity in the presence of CRY1."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         78
FT                   /note="S->E: Phosphomimetic mutant which severely impairs
FT                   DNA binding and CLOCK-ARNTL/BMAL1 transcriptional
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         88
FT                   /note="M->F: No effect on CLOCK binding."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         90
FT                   /note="S->E: Phosphomimetic mutant with no effect on DNA
FT                   binding or CLOCK-ARNTL/BMAL1 transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         125
FT                   /note="L->H: Impaired CLOCK binding."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         611
FT                   /note="A->S,T: Increased desensitization to CRY1, in the
FT                   presence of CLOCK. Approximately 2-fold increase in CLOCK-
FT                   ARNTL/BMAL1 transcriptional activity in the absence of
FT                   CRY1; when associated with E-407."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         612
FT                   /note="G->E: Increased desensitization to CRY1, in the
FT                   presence of CLOCK. Approximately 2-fold increase in CLOCK-
FT                   ARNTL/BMAL1 transcriptional activity in the absence of
FT                   CRY1."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   CONFLICT        69
FT                   /note="R -> G (in Ref. 2; AAC51213)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        123
FT                   /note="K -> R (in Ref. 1; BAA19935)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        173
FT                   /note="S -> P (in Ref. 1; BAA19939)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        259
FT                   /note="K -> N (in Ref. 1; BAA19938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        264
FT                   /note="D -> N (in Ref. 1; BAA19938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        418
FT                   /note="S -> N (in Ref. 1; BAA19937)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        513..514
FT                   /note="SP -> LR (in Ref. 2; AAC51213)"
FT                   /evidence="ECO:0000305"
FT   HELIX           71..98
FT                   /evidence="ECO:0007744|PDB:4H10"
FT   HELIX           100..103
FT                   /evidence="ECO:0007744|PDB:4H10"
FT   HELIX           111..125
FT                   /evidence="ECO:0007744|PDB:4H10"
SQ   SEQUENCE   626 AA;  68762 MW;  820F0E07DC6265A6 CRC64;
     MADQRMDISS TISDFMSPGP TDLLSSSLGT SGVDCNRKRK GSSTDYQESM DTDKDDPHGR
     LEYTEHQGRI KNAREAHSQI EKRRRDKMNS FIDELASLVP TCNAMSRKLD KLTVLRMAVQ
     HMKTLRGATN PYTEANYKPT FLSDDELKHL ILRAADGFLF VVGCDRGKIL FVSESVFKIL
     NYSQNDLIGQ SLFDYLHPKD IAKVKEQLSS SDTAPRERLI DAKTGLPVKT DITPGPSRLC
     SGARRSFFCR MKCNRPSVKV EDKDFPSTCS KKKADRKSFC TIHSTGYLKS WPPTKMGLDE
     DNEPDNEGCN LSCLVAIGRL HSHVVPQPVN GEIRVKSMEY VSRHAIDGKF VFVDQRATAI
     LAYLPQELLG TSCYEYFHQD DIGHLAECHR QVLQTREKIT TNCYKFKIKD GSFITLRSRW
     FSFMNPWTKE VEYIVSTNTV VLANVLEGGD PTFPQLTASP HSMDSMLPSG EGGPKRTHPT
     VPGIPGGTRA GAGKIGRMIA EEIMEIHRIR GSSPSSCGSS PLNITSTPPP DASSPGGKKI
     LNGGTPDIPS SGLLSGQAQE NPGYPYSDSS SILGENPHIG IDMIDNDQGS SSPSNDEAAM
     AVIMSLLEAD AGLGGPVDFS DLPWPL
//
